secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001564590-22-008037
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO reports Q4 net income $294M on AbbVie deal; cash $849M into 2025
--------------------------------------------------------------------------

- Q4 2021 net income $294M ($6.87 basic EPS) vs net loss $46.2M in Q4 2020; revenue $398.7M (incl $370M AbbVie upfront).
- Cash, equivalents & marketable securities $849.3M at Dec 31, 2021; runway into 2025.
- Closed eye care collaboration with AbbVie: $370M upfront + up to $1.38B milestones; two pivotal trials (ATMOSPHERE, ASCENT) for wet AMD.
- RGX-202: FDA cleared IND, granted Rare Pediatric Disease & Orphan Drug designations; Phase I/II AFFINITY DUCHENNE trial to start H1 2022.
- RGX-314 suprachoroidal: Phase II AAVIATE (wet AMD) & ALTITUDE (DR) show reduced treatment burden; enrollment in higher-dose cohorts ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000156459022008037/0001564590-22-008037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000156459022008037/rgnx-8k_20220301.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-008037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer